Showing 3941-3950 of 8897 results for "".
- MEL-SELF Analysis: Comparable Outcomes Between Affordable and Premium Dermatoscopeshttps://practicaldermatology.com/news/analysis-shows-comparable-outcomes-between-affordable-and-premium-dermatoscopes/2484733/A new randomized study embedded within the MEL-SELF trial suggests both low-cost and high-cost dermatoscopes enabled patients with a history of early-stage melanoma to effectively capture images for remote dermatologic assessment.
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t
- Lupus-like Skin Disease in MDS/CMML Linked to Clonal Inflammation: Studyhttps://practicaldermatology.com/news/lupuslike-skin-disease-in-mdscmml-linked-to-clonal-inflammation/2484592/Lupus-like manifestations in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) appear to represent a distinct clinical entity driven by clonal hematopoiesis rather than classic autoimmunity, according to a new case-control study
- SCRATCH-AD: Rapid-Onset Anti-Itch and Anti-Inflammatory Effects of Ruxolitinib Creamhttps://practicaldermatology.com/news/scratch-ad-rapid-onset-anti-itch-and-anti-inflammatory-effects-of-ruxolitinib-cream/2484591/Results from the SCRATCH-AD study suggested that ruxolitinib cream 1.5% provided itch relief, as well as broader improvements in atopic dermatitis (AD) severity The SCRATCH-AD study evaluated how quickly ruxolitinib 1.5% cream
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://practicaldermatology.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Skin of Color Society Media Day Analyzes Latest Trendshttps://practicaldermatology.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum